Literature DB >> 30846477

Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy.

Fabio Malavasi1, Angelo Corso Faini2.   

Abstract

Antibody therapy is a treatment option for several diseases, including multiple myeloma. The logic behind it is relatively simple: A target molecule is selected because of its expression on tumor cells, and the antibody delivers cytotoxic effects. Therapeutic results in multiple myeloma indicate that the anti-CD38 antibodies may have relevant immunotherapeutic properties.See related article by Moreno et al., p. 3176. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30846477     DOI： 10.1158/1078-0432.CCR-19-0260

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma.

Authors:  Michelle Kinder; Nizar J Bahlis; Fabio Malavasi; Bart De Goeij; Alexander Babich; Jocelyn Sendecki; Joshua Rusbuldt; Kevin Bellew; Colleen Kane; Niels W C J Van de Donk
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

Review 2.  Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.

Authors:  Alessandra Romano; Paola Storti; Valentina Marchica; Grazia Scandura; Laura Notarfranchi; Luisa Craviotto; Francesco Di Raimondo; Nicola Giuliani
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

3.  Editorial: Immunotherapy in Multiple Myeloma.

Authors:  Nicola Giuliani; Fabio Malavasi
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

4.  Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.

Authors:  Nicolas Stocker; Béatrice Gaugler; Laure Ricard; Frédéric de Vassoigne; Zora Marjanovic; Mohamad Mohty; Florent Malard
Journal:  Cancer Med       Date:  2020-01-28       Impact factor: 4.452

Review 5.  CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.

Authors:  Dario Roccatello; Roberta Fenoglio; Savino Sciascia; Carla Naretto; Daniela Rossi; Michela Ferro; Antonella Barreca; Fabio Malavasi; Simone Baldovino
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

Review 6.  CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults.

Authors:  Francesco Lanza; Enrico Maffini; Michela Rondoni; Evita Massari; Angelo Corso Faini; Fabio Malavasi
Journal:  Cancers (Basel)       Date:  2020-01-28       Impact factor: 6.639

Review 7.  The Circular Life of Human CD38: From Basic Science to Clinics and Back.

Authors:  Alberto L Horenstein; Angelo C Faini; Fabio Morandi; Cristiano Bracci; Francesco Lanza; Nicola Giuliani; Aneel Paulus; Fabio Malavasi
Journal:  Molecules       Date:  2020-10-21       Impact factor: 4.411

8.  Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.

Authors:  Kazutaka Sunami; Kenshi Suzuki; Masaki Ri; Morio Matsumoto; Chihiro Shimazaki; Hideki Asaoku; Hirohiko Shibayama; Kenichi Ishizawa; Hiroyuki Takamatsu; Takashi Ikeda; Dai Maruyama; Hitomi Kaneko; Michihiro Uchiyama; Toru Kiguchi; Satoshi Iyama; Hirokazu Murakami; Keishiro Takahashi; Keisuke Tada; Sandrine Macé; Hélène Guillemin-Paveau; Shinsuke Iida
Journal:  Cancer Sci       Date:  2020-10-15       Impact factor: 6.716
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.